Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Axon Drugs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Aging Publishes Phase II Results for AADvac1, a First-in-Man Alzheimer's Tau Vaccine Developed by Axon Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Axon Drugs"},{"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suven Life Sciences Announces Phase 3 Clinical Trial of SUVN-502 for Treatment of Agitation and Aggression in Alzheimer\u2019s Type Dementias","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Suven Life Sciences Limited"},{"company":"Dr. Reddy's Laboratories","sponsor":"MediCane Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"}]

Dr. Reddy's Laboratories

Contact Supplier

Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

$Dr. Reddy\'s Laboratories$

Digital Content

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany

Details:

As part of a collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support.

Lead Product(s): Medical Cannabis Product

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: MediCane Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 01, 2022

Dr Reddy Company Banner

CPhI Worldwide 2022

Booth # 80B60

envelop Contact Supplier

Suven Life Sciences Limited

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Suven Life Sciences Announces Phase 3 Clinical Trial of SUVN-502 for Treatment of Agitation and Aggression in Alzheimer’s Type Dementias

Details:

SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.

Lead Product(s): Masupirdine,Donepezil,Memantine Hydrochloride

Therapeutic Area: Neurology Product Name: SUVN-502

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 16, 2021

ASK
US

Upload
your Pipeline Activity

Axon Drugs

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Nature Aging Publishes Phase II Results for AADvac1, a First-in-Man Alzheimer's Tau Vaccine Developed by Axon Neuroscience

Details:

AADvac1 vaccine demonstrates robust antibody response, excellent safety profile and highly significant impact on neurodegeneration in Alzheimer's disease.

Lead Product(s): AADvac1

Therapeutic Area: Neurology Product Name: AADvac1

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY